Latest Reimbursement News

Ansell Limited delivered a robust FY25 performance driven by organic growth, successful Kimberly-Clark PPE integration, and productivity gains, while advancing sustainability goals and managing trade headwinds.

Proteomics International Laboratories has secured ISO 15189 certification and launched PromarkerD and PromarkerEso nationally in Australia, while advancing US reimbursement pathways and preparing for leadership transition.

Artrya Limited has secured FDA clearance for its Salix Coronary Plaque module and raised $80 million to fuel its U.S. commercial expansion, marking a pivotal step in its transition from development to revenue generation.

Boom Logistics reports steady revenue growth and significant capital expenditure cuts in Q1 FY26, while advancing a share buyback and navigating leadership changes.

Woodside Energy Group has sealed a strategic partnership with US infrastructure giant Williams, selling stakes in Louisiana LNG and Driftwood Pipeline for $378 million, accelerating the project’s path to first LNG in 2029.

Lumos Diagnostics reported steady quarterly revenue with a 300% surge in product sales, driven by its flagship FebriDx® test. The company inked a landmark US$317 million exclusive U.S. distribution agreement and awaits FDA feedback on its CLIA waiver application.

Miramar Resources has secured a $250,000 government refund for its Bangemall geophysical survey, revealing promising Norilsk-style nickel-copper-PGE conductors. The company advances exploration and nears a JV deal with Sumitomo Metal Mining Oceania.

4DMedical secures a major commercial breakthrough with Stanford University adopting its FDA-cleared CT, VQ™ technology, while its partnership with AstraZeneca rapidly scales lung screening across Brazil.

Mesoblast Limited reports a 69% jump in net revenues from its pioneering cell therapy Ryoncil in Q1 FY2026, propelled by expanded physician adoption and new reimbursement pathways. The company also secures convertible note funding and plans pivotal adult trials.

Botanix Pharmaceuticals reports a strong start to FY26 with a 50% surge in Sofdra prescriptions and a 65% rise in net revenue, underpinned by a larger sales team and operational efficiencies.

PainChek Limited has confirmed FDA De Novo classification for its PainChek Adult App, promptly disclosing the material regulatory milestone to the ASX and signalling a significant step towards US market entry.

Aroa Biosurgery delivered a robust September quarter with strong cash flow and record sales of its Myriad product, while reaffirming its FY26 revenue and EBITDA guidance. The company also highlighted a promising US Medicare reimbursement proposal for its Symphony product.